BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bassani TB, Gradowski RW, Zaminelli T, Barbiero JK, Santiago RM, Boschen SL, da Cunha C, Lima MM, Andreatini R, Vital MA. Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats. Brain Res 2014;1593:95-105. [PMID: 25301688 DOI: 10.1016/j.brainres.2014.09.068] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Barbiero JK, Ramos DC, Boschen S, Bassani T, Da Cunha C, Vital MABF. Fenofibrate promotes neuroprotection in a model of rotenone-induced Parkinson's disease. Behav Pharmacol 2022. [PMID: 36094044 DOI: 10.1097/FBP.0000000000000699] [Reference Citation Analysis]
2 Kamal RE, Menze E, Albohy A, Ahmed HI, Azab SS. Title: Neuroprotective repositioning and anti-tau effect of carvedilol on rotenone induced neurotoxicity in rats: Insights from an insilico&in vivo anti-Parkinson's disease study. Eur J Pharmacol 2022;:175204. [PMID: 35964655 DOI: 10.1016/j.ejphar.2022.175204] [Reference Citation Analysis]
3 Ablat N, Liu R, Ablimit M, Sun Y, Xu F, Zhao X, Han H, Pu X. Preventive effects of a standardized flavonoid extract of safflower in rotenone-induced Parkinson's disease rat model. Neuropharmacology 2022. [DOI: 10.1016/j.neuropharm.2022.109209] [Reference Citation Analysis]
4 Casanova Y, Negro S, Slowing K, García-garcía L, Fernández-carballido A, Rahmani M, Barcia E. Micro- and Nano-Systems Developed for Tolcapone in Parkinson’s Disease. Pharmaceutics 2022;14:1080. [DOI: 10.3390/pharmaceutics14051080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhang Z, Peng Q, Huo D, Jiang S, Ma C, Chang H, Chen K, Li C, Pan Y, Zhang J. Melatonin Regulates the Neurotransmitter Secretion Disorder Induced by Caffeine Through the Microbiota-Gut-Brain Axis in Zebrafish (Danio rerio). Front Cell Dev Biol 2021;9:678190. [PMID: 34095150 DOI: 10.3389/fcell.2021.678190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pérez-Lloret S, Cardinali DP. Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson's Disease. Front Pharmacol 2021;12:650597. [PMID: 33935759 DOI: 10.3389/fphar.2021.650597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
7 Tancheva L, Lazarova M, Saso L, Kalfin R, Stefanova M, Uzunova D, Atanasov AG. Beneficial Effect of Melatonin on Motor and Memory Disturbances in 6-OHDA-Lesioned Rats. J Mol Neurosci 2021;71:702-12. [PMID: 33403591 DOI: 10.1007/s12031-020-01760-z] [Reference Citation Analysis]
8 Ashhar MU, Kumar S, Ali J, Baboota S. CCRD based development of bromocriptine and glutathione nanoemulsion tailored ultrasonically for the combined anti-parkinson effect. Chem Phys Lipids 2021;235:105035. [PMID: 33400967 DOI: 10.1016/j.chemphyslip.2020.105035] [Reference Citation Analysis]
9 Noseda ACD, Rodrigues LS, Targa ADS, Ilkiw JL, Fagotti J, Dos Santos PD, Cecon E, Markus RP, Solimena M, Jockers R, Lima MMS. MT2 melatonin receptors expressed in the olfactory bulb modulate depressive-like behavior and olfaction in the 6-OHDA model of Parkinson's disease. Eur J Pharmacol 2021;891:173722. [PMID: 33159932 DOI: 10.1016/j.ejphar.2020.173722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Percário S, da Silva Barbosa A, Varela ELP, Gomes ARQ, Ferreira MES, de Nazaré Araújo Moreira T, Dolabela MF. Oxidative Stress in Parkinson's Disease: Potential Benefits of Antioxidant Supplementation. Oxid Med Cell Longev 2020;2020:2360872. [PMID: 33101584 DOI: 10.1155/2020/2360872] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
11 Miyazaki I, Asanuma M. The Rotenone Models Reproducing Central and Peripheral Features of Parkinson’s Disease. NeuroSci 2020;1:1-14. [DOI: 10.3390/neurosci1010001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Miranda-Díaz AG, García-Sánchez A, Cardona-Muñoz EG. Foods with Potential Prooxidant and Antioxidant Effects Involved in Parkinson's Disease. Oxid Med Cell Longev 2020;2020:6281454. [PMID: 32832004 DOI: 10.1155/2020/6281454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
13 Hadoush H, Lababneh T, Banihani SA, Al-Jarrah M, Jamous M. Melatonin and dopamine serum level associations with motor, cognitive, and sleep dysfunctions in patients with Parkinson's disease: A cross-sectional research study. NeuroRehabilitation 2020;46:539-49. [PMID: 32538881 DOI: 10.3233/NRE-203075] [Reference Citation Analysis]
14 Chen YR, Lai PL, Chien Y, Lee PH, Lai YH, Ma HI, Shiau CY, Wang KC. Improvement of Impaired Motor Functions by Human Dental Exfoliated Deciduous Teeth Stem Cell-Derived Factors in a Rat Model of Parkinson's Disease. Int J Mol Sci 2020;21:E3807. [PMID: 32471263 DOI: 10.3390/ijms21113807] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
15 Li L, Zhao Z, Ma J, Zheng J, Huang S, Hu S, Gu Q, Chen S. Elevated Plasma Melatonin Levels Are Correlated With the Non-motor Symptoms in Parkinson's Disease: A Cross-Sectional Study. Front Neurosci. 2020;14:505. [PMID: 32508583 DOI: 10.3389/fnins.2020.00505] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
16 Niu YJ, Zhou W, Nie ZW, Shin KT, Cui XS. Melatonin enhances mitochondrial biogenesis and protects against rotenone-induced mitochondrial deficiency in early porcine embryos. J Pineal Res 2020;68:e12627. [PMID: 31773776 DOI: 10.1111/jpi.12627] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
17 Vieira JCF, Bassani TB, Santiago RM, de O. Guaita G, Zanoveli JM, da Cunha C, Vital MA. Anxiety-like behavior induced by 6-OHDA animal model of Parkinson’s disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety. Behavioural Brain Research 2019;371:111981. [DOI: 10.1016/j.bbr.2019.111981] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
18 Cardinali DP. Melatonin: Clinical Perspectives in Neurodegeneration. Front Endocrinol (Lausanne) 2019;10:480. [PMID: 31379746 DOI: 10.3389/fendo.2019.00480] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 19.7] [Reference Citation Analysis]
19 Galts CP, Bettio LE, Jewett DC, Yang CC, Brocardo PS, Rodrigues ALS, Thacker JS, Gil-mohapel J. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neuroscience & Biobehavioral Reviews 2019;102:56-84. [DOI: 10.1016/j.neubiorev.2019.04.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 15.7] [Reference Citation Analysis]
20 Morais LH, Hara DB, Bicca MA, Poli A, Takahashi RN. Early signs of colonic inflammation, intestinal dysfunction, and olfactory impairments in the rotenone-induced mouse model of Parkinson's disease. Behav Pharmacol 2018;29:199-210. [PMID: 29543651 DOI: 10.1097/FBP.0000000000000389] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
21 Genario R, Giacomini AC, Demin KA, dos Santos BE, Marchiori NI, Volgin AD, Bashirzade A, Amstislavskaya TG, de Abreu MS, Kalueff AV. The evolutionarily conserved role of melatonin in CNS disorders and behavioral regulation: Translational lessons from zebrafish. Neuroscience & Biobehavioral Reviews 2019;99:117-27. [DOI: 10.1016/j.neubiorev.2018.12.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
22 Mahmood D, Muhammad BY, Alghani M, Anwar J, el-Lebban N, Haider M. Advancing role of melatonin in the treatment of neuropsychiatric disorders. Egyptian Journal of Basic and Applied Sciences 2019;3:203-18. [DOI: 10.1016/j.ejbas.2016.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
23 Günaydın C, Avcı B, Bozkurt A, Önger ME, Balcı H, Bilge SS. Effects of agomelatine in rotenone-induced Parkinson's disease in rats. Neurosci Lett 2019;699:71-6. [PMID: 30716425 DOI: 10.1016/j.neulet.2019.01.057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
24 Crowley EK, Nolan YM, Sullivan AM. Exercise as a therapeutic intervention for motor and non-motor symptoms in Parkinson's disease: Evidence from rodent models. Prog Neurobiol 2019;172:2-22. [PMID: 30481560 DOI: 10.1016/j.pneurobio.2018.11.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
25 Horst CH, Schlemmer F, de Aguiar Montenegro N, Domingues ACM, Ferreira GG, da Silva Ribeiro CY, de Andrade RR, Del Bel Guimarães E, Titze-de-almeida SS, Titze-de-almeida R. Signature of Aberrantly Expressed microRNAs in the Striatum of Rotenone-Induced Parkinsonian Rats. Neurochem Res 2018;43:2132-40. [DOI: 10.1007/s11064-018-2638-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
26 Zhang Z, Rasmussen L, Saraswati M, Koehler RC, Robertson C, Kannan S. Traumatic Injury Leads to Inflammation and Altered Tryptophan Metabolism in the Juvenile Rabbit Brain. J Neurotrauma 2018. [PMID: 30019623 DOI: 10.1089/neu.2017.5450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
27 Abdel-rahman M, Galhom RA, Nasr El-din WA, Mohammed Ali MH, Abdel-hamid AES. Therapeutic efficacy of olfactory stem cells in rotenone induced Parkinsonism in adult male albino rats. Biomedicine & Pharmacotherapy 2018;103:1178-86. [DOI: 10.1016/j.biopha.2018.04.160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
28 Abd Allah ESH, Mahmoud AM. Melatonin attenuates chronic immobilization stress-induced muscle atrophy in rats: Influence on lactate-to-pyruvate ratios and Na+/K+ ATPase activity. Pathophysiology 2018;25:353-7. [PMID: 29921483 DOI: 10.1016/j.pathophys.2018.06.002] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Turnes JM, Bassani TB, Souza LC, Vital MABF. Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats. J Pharm Pharmacol. 2018;70:1059-1068. [PMID: 29766510 DOI: 10.1111/jphp.12936] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Souza LC, Martynhak BJ, Bassani TB, Turnes JDM, Machado MM, Moura E, Andreatini R, Vital MA. Agomelatine's effect on circadian locomotor rhythm alteration and depressive-like behavior in 6-OHDA lesioned rats. Physiology & Behavior 2018;188:298-310. [DOI: 10.1016/j.physbeh.2018.02.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
31 Salama RM, Tadros MG, Schaalan MF, Bahaa N, Abdel‐tawab AM, Khalifa AE. Potential neuroprotective effect of androst‐5‐ene‐3β, 17β‐diol (ADIOL) on the striatum, and substantia nigra in Parkinson's disease rat model. J Cell Physiol 2018;233:5981-6000. [DOI: 10.1002/jcp.26412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
32 Taniguti EH, Ferreira YS, Stupp IJV, Fraga-Junior EB, Mendonça CB, Rossi FL, Ynoue HN, Doneda DL, Lopes L, Lima E, Buss ZS, Vandresen-Filho S. Neuroprotective effect of melatonin against lipopolysaccharide-induced depressive-like behavior in mice. Physiol Behav 2018;188:270-5. [PMID: 29458118 DOI: 10.1016/j.physbeh.2018.02.034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
33 Barcia E, Boeva L, García-García L, Slowing K, Fernández-Carballido A, Casanova Y, Negro S. Nanotechnology-based drug delivery of ropinirole for Parkinson's disease. Drug Deliv 2017;24:1112-23. [PMID: 28782388 DOI: 10.1080/10717544.2017.1359862] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
34 Sarbishegi M, Charkhat Gorgich EA, Khajavi O, Komeili G, Salimi S. The neuroprotective effects of hydro-alcoholic extract of olive (Olea europaea L.) leaf on rotenone-induced Parkinson’s disease in rat. Metab Brain Dis 2018;33:79-88. [DOI: 10.1007/s11011-017-0131-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
35 Trotti LM, Karroum EG. Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases. Curr Neurol Neurosci Rep 2016;16:63. [PMID: 27180068 DOI: 10.1007/s11910-016-0664-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
36 Shen Y, Guo X, Han C, Wan F, Ma K, Guo S, Wang L, Xia Y, Liu L, Lin Z, Huang J, Xiong N, Wang T. The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease. Cell Mol Life Sci 2017;74:3741-68. [PMID: 28623510 DOI: 10.1007/s00018-017-2549-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wu LL, Gong W, Shen SP, Wang ZH, Yao JX, Wang J, Yu J, Gao R, Wu G. Multiple metal exposures and their correlation with monoamine neurotransmitter metabolism in Chinese electroplating workers. Chemosphere 2017;182:745-52. [PMID: 28535482 DOI: 10.1016/j.chemosphere.2017.04.112] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
38 Dey A, Bhattacharya R, Mukherjee A, Pandey DK. Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions. Biotechnol Adv 2017;35:178-216. [PMID: 28043897 DOI: 10.1016/j.biotechadv.2016.12.005] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 15.7] [Reference Citation Analysis]
39 Mack JM, Schamne MG, Sampaio TB, Pértile RA, Fernandes PA, Markus RP, Prediger RD. Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms. Oxid Med Cell Longev 2016;2016:3472032. [PMID: 27829983 DOI: 10.1155/2016/3472032] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
40 Stefanovic B, Spasojevic N, Jovanovic P, Jasnic N, Djordjevic J, Dronjak S. Melatonin mediated antidepressant-like effect in the hippocampus of chronic stress-induced depression rats: Regulating vesicular monoamine transporter 2 and monoamine oxidase A levels. European Neuropsychopharmacology 2016;26:1629-37. [DOI: 10.1016/j.euroneuro.2016.07.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
41 Targa AD, Rodrigues LS, Noseda ACD, Aurich MF, Andersen ML, Tufik S, da Cunha C, Lima MM. Unraveling a new circuitry for sleep regulation in Parkinson's disease. Neuropharmacology 2016;108:161-71. [DOI: 10.1016/j.neuropharm.2016.04.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
42 Ablat N, Lv D, Ren R, Xiaokaiti Y, Ma X, Zhao X, Sun Y, Lei H, Xu J, Ma Y, Qi X, Ye M, Xu F, Han H, Pu X. Neuroprotective Effects of a Standardized Flavonoid Extract from Safflower against a Rotenone-Induced Rat Model of Parkinson's Disease. Molecules 2016;21:E1107. [PMID: 27563865 DOI: 10.3390/molecules21091107] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
43 Dhanalakshmi C, Janakiraman U, Manivasagam T, Justin Thenmozhi A, Essa MM, Kalandar A, Khan MA, Guillemin GJ. Vanillin Attenuated Behavioural Impairments, Neurochemical Deficts, Oxidative Stress and Apoptosis Against Rotenone Induced Rat Model of Parkinson's Disease. Neurochem Res 2016;41:1899-910. [PMID: 27038927 DOI: 10.1007/s11064-016-1901-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
44 Carriere CH, Kang NH, Niles LP. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease. Brain Res 2016;1633:115-25. [PMID: 26740407 DOI: 10.1016/j.brainres.2015.12.036] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
45 Noseda AC, Targa AD, Rodrigues LS, Aurich MF, Lima MM. REM sleep deprivation promotes a dopaminergic influence in the striatal MT2 anxiolytic-like effects. Sleep Sci 2016;9:47-54. [PMID: 27226821 DOI: 10.1016/j.slsci.2015.10.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
46 Mandal S, Das Mandal S, Chuttani K, Sawant KK, Subudhi BB. Neuroprotective effect of ibuprofen by intranasal application of mucoadhesive nanoemulsion in MPTP induced Parkinson model. Journal of Pharmaceutical Investigation 2016;46:41-53. [DOI: 10.1007/s40005-015-0212-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
47 Moretti M, Neis VB, Matheus FC, Cunha MP, Rosa PB, Ribeiro CM, Rodrigues AL, Prediger RD. Effects of Agmatine on Depressive-Like Behavior Induced by Intracerebroventricular Administration of 1-Methyl-4-phenylpyridinium (MPP(+)). Neurotox Res 2015;28:222-31. [PMID: 26156429 DOI: 10.1007/s12640-015-9540-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
48 Johnson ME, Bobrovskaya L. An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. Neurotoxicology 2015;46:101-16. [PMID: 25514659 DOI: 10.1016/j.neuro.2014.12.002] [Cited by in Crossref: 145] [Cited by in F6Publishing: 166] [Article Influence: 18.1] [Reference Citation Analysis]